Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
2 other identifiers
observational
1,500
15 countries
84
Brief Summary
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2014
Longer than P75 for all trials
84 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 21, 2014
CompletedFirst Posted
Study publicly available on registry
February 25, 2014
CompletedStudy Start
First participant enrolled
March 4, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2038
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2038
June 12, 2026
June 1, 2026
24.8 years
February 21, 2014
June 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Improvement in patient's quality of life (QoL) during the study as compared with baseline
Change in quality of life assessments during the study as compared with baseline
up to 3 years
Other Outcomes (3)
Change in parkinson's disease symptoms as determined by UPDRS scores during the study as compared with baseline
up to 3 years
Change in medication usage during the study as compared with baseline
up to 3 years
Impression of change scores during the study as compared with baseline
3 years
Study Arms (1)
Parkinson's disease
Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.
Interventions
Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
Eligibility Criteria
Patients with symptoms of Parkinson's disease that are not adequately controlled with medication
You may qualify if:
- Meets criteria established in locally applicable Vercise System Direction for Use
- At least 18 years old
You may not qualify if:
- Meets any contraindication in the Vercise System locally applicable Directions for Use
- Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (84)
Neurology and Pain Specialty
Aliso Viejo, California, 92656, United States
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
University of Colorado
Aurora, Colorado, 80220, United States
St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81501, United States
University of Florida Shands Hospital
Gainesville, Florida, 32610, United States
Mayo Clinic, Jacksonville
Jacksonville, Florida, 32224, United States
University of Miami Hospital
Miami, Florida, 33136, United States
Tallahassee Neurological Clinic, PA
Tallahassee, Florida, 32308, United States
University of South Florida
Tampa, Florida, 33612, United States
St. Luke Regional Medical Center
Boise, Idaho, 83702, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
Methodist Hospital of Indianapolis
Indianapolis, Indiana, 46202, United States
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
St. Louis University Hospital
St Louis, Missouri, 63110, United States
Albany Medical College
Albany, New York, 12208, United States
Northwell Health Neuroscience Institute
Great Neck, New York, 11021, United States
University at Buffalo
Williamsville, New York, 14221, United States
Wake Forest University School of Medicine
Winston-Salem, North Carolina, 27157, United States
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Ohio State University
Columbus, Ohio, 43210, United States
Vanderbilt University
Nashville, Tennessee, 37232, United States
Houston Methodist Research Institute
Houston, Texas, 77030, United States
University of Texas Health Medical Arts and Research Center
San Antonio, Texas, 78229, United States
Texas Institute for Neurological Disorders
Sherman, Texas, 75092, United States
University of Virginia Medical Center
Charlottesville, Virginia, 22903, United States
Evergreen Health
Kirkland, Washington, 98034, United States
University of Washington Medical Center
Seattle, Washington, 98195, United States
Inland Northwest Research
Spokane, Washington, 99202, United States
Fundacion Ineco-Research Facility
Buenos Aires, Argentina
A.o. LKH Univ.-Kliniken Innsbruck
Innsbruck, Austria
AZ Sint-Lucas
Ghent, Belgium
UZ Gasthuisberg
Leuven, Belgium
AZ Delta
Roeselare, Belgium
Queen Elizabeth II Health Sciences Center
Halifax, Canada
Hopital de Enfant-Jesus
Québec, Canada
CHU Henri Mondor
Créteil, France
Hopital Neurologique Pierre Wertheimer
Lyon, France
CHU La Timone Hospital
Marseille, France
Fondation Ophtalmologique Adolphe de Rothschild
Paris, France
CHRU Hopital Pontchaillou
Rennes, France
University Berlin, Charite Virchow Standort, Wedding
Berlin, Germany
Uniklinik Köln
Cologne, Germany
Universitätsklinikum Düsseldorf
Düsseldorf, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitätsklinik Eppendorf
Hamburg, Germany
St. Barbara-Klinik Hamm-Heessen
Hamm, Germany
Universitätsklinikum Campus Kiel
Kiel, Germany
Johannes Gutenberg Universitaet Mainz
Mainz, Germany
Universitaetsklinikum Giessen und Marburg GmbH
Marburg, Germany
Evangelisches Krankenhaus Oldenburg
Oldenburg, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Medical School of University PECS
Pécs, Hungary
Hadassah Hebrew University Medical Center
Jerusalem, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Sheba Medical Center
Tel Litwinsky, Israel
Villa Margherita
Arcugnano, Italy
Azienda Ospedaliero-Universitaria di Ferrara
Ferrara, Italy
Ospedale Dell Angelo
Mestre, Italy
IRCCS Istituto Ortopedico Galeazzi
Milan, Italy
Fondazione Istituto Neurologico Casimiro Mondino
Pavia, Italy
Policlinico Universitario Agostino Gemelli
Rome, Italy
Osp. S. Maria Della Misericordia
Udine, Italy
10 Military Clinical Hospital Bydgoszcz
Bydgoszcz, Poland
Podmiot Leczniczy Copernicus Sp. z o.o.
Gdansk, Poland
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie
Warsaw, Poland
Samsung Medical Center
Seoul, South Korea
Seoul ASAN Medical Center
Seoul, South Korea
Yonsei University Severance Hospital
Seoul, South Korea
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital De Bellvitge
Barcelona, Spain
Centro Especial Ramon y Cajal
Madrid, Spain
Hospital Clinico San Carlos
Madrid, Spain
University Hospital Virgen Arrixaca
Murcia, Spain
Hospital General De Asturias
Oviedo, Spain
Bahcesehir University Hospital Medical Park Goztepe
Istanbul, Turkey (Türkiye)
Koc University Hospital
Istanbul, Turkey (Türkiye)
Southmead Hospital Bristol
Bristol, United Kingdom
Queen Elizabeth University Hospital
Glasgow, United Kingdom
The Walton Centre
Liverpool, United Kingdom
Charing Cross Hospital
London, United Kingdom
King's College Hospital London
London, United Kingdom
St. Georges Hospital
London, United Kingdom
Royal Victoria Infirmary
Newcastle, United Kingdom
John Radcliffe Hospital
Oxford, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Natalie Bloom Lyons
Boston Scientific Neuromodulation Corporation
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 21, 2014
First Posted
February 25, 2014
Study Start
March 4, 2014
Primary Completion (Estimated)
December 1, 2038
Study Completion (Estimated)
December 1, 2038
Last Updated
June 12, 2026
Record last verified: 2026-06